Abstract
Cabazitaxel has recently been approved by FDA for the treatment of docetaxel resistant hormone-refractory prostate cancer. It has been developed by Sanofi-Aventis under the trade name of Jevtana. It is given in combination with prednisone/prednisolone and has passed the clinical trial over well-known drug mitoxantrone. This drug is a microtubule depolymerization inhibitor, which can penetrate blood brain barrier (BBB). The FDA granted fast track designation to this drug in November 2009 and thereafter, new drug application submission was done in March 2010. Priority review to this drug was granted in April 2010 and finally in July 2010 it was approved by FDA. It is available in the form of injection in the dose of 60 mg/1.5 mL, which should be diluted prior to its use by the diluents supplied along with the injection. It is a second-line drug and has proven to be effective in patients experiencing docetaxel based treatment failure.
Keywords: Prostate cancer, Jevtana, Sanofi-aventis, Taxanes, Cabazitaxel, XRP-6258
Mini-Reviews in Medicinal Chemistry
Title:Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer
Volume: 13 Issue: 6
Author(s): Manav Malhotra, Richa Dhingra, Tina Sharma, Aakash Deep, Balasubramanian Narasimhan, Priyanka Phogat and Prabodh Chander Sharma
Affiliation:
Keywords: Prostate cancer, Jevtana, Sanofi-aventis, Taxanes, Cabazitaxel, XRP-6258
Abstract: Cabazitaxel has recently been approved by FDA for the treatment of docetaxel resistant hormone-refractory prostate cancer. It has been developed by Sanofi-Aventis under the trade name of Jevtana. It is given in combination with prednisone/prednisolone and has passed the clinical trial over well-known drug mitoxantrone. This drug is a microtubule depolymerization inhibitor, which can penetrate blood brain barrier (BBB). The FDA granted fast track designation to this drug in November 2009 and thereafter, new drug application submission was done in March 2010. Priority review to this drug was granted in April 2010 and finally in July 2010 it was approved by FDA. It is available in the form of injection in the dose of 60 mg/1.5 mL, which should be diluted prior to its use by the diluents supplied along with the injection. It is a second-line drug and has proven to be effective in patients experiencing docetaxel based treatment failure.
Export Options
About this article
Cite this article as:
Malhotra Manav, Dhingra Richa, Sharma Tina, Deep Aakash, Narasimhan Balasubramanian, Phogat Priyanka and Chander Sharma Prabodh, Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer, Mini-Reviews in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/1389557511313060011
DOI https://dx.doi.org/10.2174/1389557511313060011 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genistein Inhibits Cell Growth and Invasion Through Regulation of miR-27a in Pancreatic Cancer Cells
Current Pharmaceutical Design Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma
Current Radiopharmaceuticals Natural Hydrogels Applied in Photodynamic Therapy
Current Medicinal Chemistry Application of Diffusion Weighted Imaging in Prostate Cancer Bone Metastasis: Detection and Therapy Evaluation
Anti-Cancer Agents in Medicinal Chemistry Pancreatic Cancer Metastasis: Are we being Pre-EMTed?
Current Pharmaceutical Design Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Breakthrough Pain
Current Drug Therapy Identification and Characterization of Novel Antioxidant Peptides Involved in Redox Homeostasis of Frog, Limnonectes fragilis
Protein & Peptide Letters Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Assessing the Neuronal Serotonergic Target-based Antidepressant Stratagem: Impact of In Vivo Interaction Studies and Knockout Models
Current Neuropharmacology Preface
Current Drug Targets Naturally-occurring Dimers of Flavonoids as Anticarcinogens
Anti-Cancer Agents in Medicinal Chemistry Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy
Mini-Reviews in Medicinal Chemistry Pharmacoepigenomics: An Interplay of Epigenetic Modulation of Drug Response and Modulation of the Epigenome by Drugs
Current Pharmaceutical Design Nur77 Family of Nuclear Hormone Receptors
Current Drug Targets - Inflammation & Allergy Green Tea (Camellia sinensis) Protects Against Arsenic Neurotoxicity via Antioxidative Mechanism and Activation of Superoxide Dismutase Activity
Central Nervous System Agents in Medicinal Chemistry A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal